Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients 48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group 28% fibrosis improvement of at least two stages across all dose groups, with a...
before we kick start the update. your upvotes/subs are appreciated. Why get subbed to to me on Tradingview? -15+ years real live trading experience -TOP Author on TradingView -professional chart break downs -key levels -no junk on my charts -frequent updates -covering FX/crypto/US stocks -24/7 uptime so constant updates So without further due. Keep it...
long-term buy and hold from 18 target is +70% near 30. get ready to buy dips later in q1 2020.
BASED ON MY TECHNICAL ANALYSIS IT'S PROBABLY THAT GO UP IN THE FUTURE